AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows ...

AstraZeneca’s immunotherapy Imfinzi is a blockbuster drug but it won’t be generating U.S. sales in bladder cancer anymore. The British pharmaceutical giant is pulling the product from the ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). Now, detailed data show exactly how Imfinzi ...

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival in early-stage NSCLC. Despite this, Imfinzi's safety profile remains consistent.

AstraZeneca AZN announced positive results from the ongoing phase III EMERALD-I study, which is evaluating Imfinzi (durvalumab) as a combination therapy in hepatocellular carcinoma (HCC), the most ...

AstraZeneca's cancer medicine Imfinzi is seen in this undated handout image provided to Reuters, June 30, 2022. AstraZeneca/Handout via REUTERS/File Photo Purchase Licensing Rights, opens new tab.

AstraZeneca's latest analysis on Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza in endometrial cancer. Improved secondary efficacy endpoints in patients with advanced or recurrent ...